Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australian HTA Revamp Aims To Speed Access To New Technologies

Executive Summary

Drug industry group Medicines Australia says that the review of the health technology assessment system must ensure that the real impact and benefits of new products for patients are taken into account in reimbursement decisions. Other areas to be explored include the use of real-world data and managing clinical and economic uncertainty.

You may also be interested in...

Australian Committee Wants HTA Review To Begin Early In 2023

At its next meeting, the Australian committee responsible for reviewing the country's health technology assessment system will discuss feedback from stakeholders, including the pharmaceutical industry, on the draft terms of reference for the review.

Australia To Speed Up Post-Market Reviews Of Reimbursed Drugs

The existing framework for assessing whether medicines should continue to be reimbursed is no longer fit for purpose and requires an overhaul if the ongoing viability of the Pharmaceutical Benefits Scheme is to be ensured, says Australia’s health department.

Australian Industry Signs Deal To Fund Access To Innovative New Drugs

Hot on the heels of Australia’s plan to overhaul the National Medicines Policy comes a new deal with the pharmaceutical industry to make new drugs available as soon as possible after approval and get patients more closely involved in reimbursement processes.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts